ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
CytoDyn Inc (QB)

CytoDyn Inc (QB) (CYDY)

0.3425
-0.0075
( -2.14% )

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.3425
Bid
0.3331
Ask
0.3425
Volume
1,128,377
0.33 Day's Range 0.3575
0.1031 52 Week Range 0.4945
Market Cap
Previous Close
0.35
Open
0.35
Last Trade
100
@
0.3425
Last Trade Time
Financial Volume
$ 382,641
VWAP
0.339107
Average Volume (3m)
2,801,457
Shares Outstanding
1,232,433,000
Dividend Yield
-
PE Ratio
-8.17
Earnings Per Share (EPS)
-0.04
Revenue
-
Net Profit
-49.84M

About CytoDyn Inc (QB)

CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that... CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
CytoDyn Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker CYDY. The last closing price for CytoDyn (QB) was $0.35. Over the last year, CytoDyn (QB) shares have traded in a share price range of $ 0.1031 to $ 0.4945.

CytoDyn (QB) currently has 1,232,433,000 shares outstanding. The market capitalization of CytoDyn (QB) is $431.35 million. CytoDyn (QB) has a price to earnings ratio (PE ratio) of -8.17.

CYDY Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0125-3.521126760560.3550.360.338549170.35209962CS
4-0.0495-12.62755102040.3920.39990.3215396570.34822729CS
120.102542.70833333330.240.4470.192528014570.32275195CS
260.201142.0494699650.14150.49450.105132270300.26552944CS
520.2083155.216095380.13420.49450.103127680870.2106677CS
156-0.0375-9.868421052630.381.30.103123018830.27064102CS
260-2.7275-88.84364820853.0710.010.103128920311.777409CS

CYDY - Frequently Asked Questions (FAQ)

What is the current CytoDyn (QB) share price?
The current share price of CytoDyn (QB) is $ 0.3425
How many CytoDyn (QB) shares are in issue?
CytoDyn (QB) has 1,232,433,000 shares in issue
What is the market cap of CytoDyn (QB)?
The market capitalisation of CytoDyn (QB) is USD 431.35M
What is the 1 year trading range for CytoDyn (QB) share price?
CytoDyn (QB) has traded in the range of $ 0.1031 to $ 0.4945 during the past year
What is the PE ratio of CytoDyn (QB)?
The price to earnings ratio of CytoDyn (QB) is -8.17
What is the reporting currency for CytoDyn (QB)?
CytoDyn (QB) reports financial results in USD
What is the latest annual profit for CytoDyn (QB)?
The latest annual profit of CytoDyn (QB) is USD -49.84M
What is the registered address of CytoDyn (QB)?
The registered address for CytoDyn (QB) is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the CytoDyn (QB) website address?
The website address for CytoDyn (QB) is www.cytodyn.com
Which industry sector does CytoDyn (QB) operate in?
CytoDyn (QB) operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VGFCQVery Good Food Company Inc (CE)
$ 0.005
(499,900.00%)
259.63k
NTPLNetplex Group Inc (CE)
$ 0.0025
(249,900.00%)
400
BIRMFBiorem Inc (PK)
$ 1.70
(154,445.45%)
9.7k
OSKADAmpliPay Group Inc (PK)
$ 1.10
(52,280.95%)
204
ZHCLFZenith Capital Corporation (CE)
$ 0.04
(39,900.00%)
750
TAYOTaylor Consulting Inc (CE)
$ 0.000001
(-99.83%)
1,000
RGFCReal Good Food Company Inc (CE)
$ 0.0001
(-99.80%)
915
BIMIBIMI International Medical Inc (CE)
$ 0.0001
(-99.67%)
1,000
COGDFCompass Gold Corporation (PK)
$ 0.0005
(-99.67%)
6.06k
SRAXSRAX Inc (CE)
$ 0.0003
(-99.40%)
58.53k
AFFUAffluence Corp (PK)
$ 0.0002
(42.86%)
324.5M
PSWWPrincipal Solar Inc (PK)
$ 0.0004
(0.00%)
202.02M
GTCHGBT Technologies Inc (PK)
$ 0.0003
(0.00%)
154.33M
DRNGDrone Guarder Inc (PK)
$ 0.0003
(50.00%)
122.77M
DPLSDarkPulse Inc (PK)
$ 0.00035
(0.00%)
122.71M

CYDY Discussion

View Posts
Monroe1 Monroe1 2 hours ago
Noo
👍️0
Monroe1 Monroe1 2 hours ago
yes
👍️0
sandtoes sandtoes 7 hours ago
lets get this a lot higher.
👍️ 1
kgromax kgromax 23 hours ago
Where is the ESMO Munich partnership announcement? Wasn't it supposed to be announced in May, with a $ billions windfall for CYDY shareholders? Where is it?
👍️0
djjazzyjeff djjazzyjeff 1 day ago
Have they recruited anyone wasn't the trial supposed to start by now
👍️0
sandtoes sandtoes 1 day ago
to the sky and beyond.
👍️ 1
Yki Yki 3 days ago
Thanks for that.
Mainstream sure does not like RKF at least what I learn here in europe.
Exciting july coming
👍️ 2
moneycrew moneycrew 4 days ago
"federal investigations and cases against alleged corporate wrongdoing that are at risk of being dropped, weakened, or otherwise modified by the Trump administration."

Is the rumor true? Nader too?
👍️0
chumppunk chumppunk 4 days ago
Awesome post.. "Uplisting requirements for CYDY"
Hi LONGS, Always seems to be confusion around uplisting requirements. I thought I would post ChatGPT’s search results here: By the way; I didn’t know that CYDY applied to uplist back in July 2020 (before my first investment)

Have a great weekend Longs!

✅ Initial Listing Requirements (after OTC ? NASDAQ uplist)

Financial Criteria (Rule 5505(a)(1)(B))

To qualify under the Market Value or Equity standards, CytoDyn must satisfy one of these options: • Price & Asset Requirements • Minimum closing price: ≥?$3.00 for 5 consecutive business days if meeting equity/net-income criteria, or ≥?$2.00 if qualifying under market-value standards. • Net tangible assets: >?$2 million (if ≥?3 years operating) or >?$5 million (if
👍️ 4
kgromax kgromax 4 days ago
If we buy more when it goes down and never sell we may be billionaires - oh wait that assumes infinite capital and infinite time…but shhhhh don’t « bash »
👍️0
sandtoes sandtoes 4 days ago
the world will fined out what we have.
👍️ 1
chumppunk chumppunk 4 days ago
Gotta thank this ole boy! "Whoa, things are lining/heating up"
There are quite a few interesting things in the mix right now, and to me the biggest has been Max Lataillade recently describing the MOA that was announced in May. I think he has caught a few eyeballs with his illustration of the compound MOA that describes leronlimab in oncology. Thanks Max!

I've mentioned before that I've grown accustomed now to re-read the press releases from CytoDyn and I gain more insights as I do. One thing from the March 18 letter that is now standing out to me is the mention of preclinical work in Stroke, and it seems to me from what I've read, that Stroke preclinicals can potentially be very short. In putting the press releases together, I am led to believe that results from preclinicals in: Glioblastoma, Stroke, TNBC synergy with immune checkpoint inhibitor, TNBC synergy with immuno-conjugate, TNBC MOA, all may be within their windows where those studies could have completed or will do so shortly.

There is so much going on it seems. We also discovered this week that CytoDyn put Prostate cancer into the pipeline at the preclinical stage. That seemed to be different from the way past announcements have been made, but frankly it isn't unexpected that they are looking into this. They had a compassionate use patient years ago I believe who had a successful outcome. I wouldn't be surprised to see Pancreatic also appear on the pipeline. The PD-L1 monotherapy ORR chart across solid cancers tells a story that is compelling for CytoDyn to supercharge due to the compound MOA of leronlimab that Max Lataillade describes.

There are a few papers too that have been mentioned in the past as moving along in the process, but we haven't yet seen published. We also wait patiently to be updated on a number of clinical trials starting, some of which are connected to academic institutions.

As the CRC trial gets underway, we should be mindful of the 2 safety checks, one at 5 patients, and the second at 20 patients. I hope that communication will flow to investors about these moments.

Another big moment is 5 year survival data from the TNBC patients. By my calculations, after looking at earlier press releases, that anniversary is in late July.

I don't know when we might hear something, but there sure seems to be an unusual number of things coming together. I smell a partnership, licensing, or other fun stuff. Just a hunch. Here's another interesting thing happening-

Within the last couple of days we have also realized that CytoDyn has recently submitted results from multiple earlier trials to clinicaltrials.gov . The table of trials marked with "Completed" status or which had "Unknown status", will eventually show many more trials "WITH RESULTS". Actually, only the Basket trial and two additional HIV extension trials remain to have their results submitted. So it seems there is more data to be made public soon.

I would expect the CRC data subset from the basket trial to be presented at ESMO GI Barcelona on July 4 before clinicaltrials.gov is updated with the basket trial results. That CRC data also has potential to demonstrate the new MOA and further solidify the notion that Leronlimab is a platform drug, which in oncology, primes tumors making them eligible for checkpoint blockade — and gives more patients a shot at immunotherapy.
Chump
👍️ 6 💯 1
djjazzyjeff djjazzyjeff 5 days ago
That's caus the sheets can't stop partnership
👍️0
fung_derf fung_derf 5 days ago
Hard to believe, but this actually seems to be forming a cup and handle.
👍️ 2
kgromax kgromax 5 days ago
Nasty shirts

Big pharma colluding to lower the price because it will go up
👍️0
djjazzyjeff djjazzyjeff 5 days ago
Why is this reed again bezinga put 3 dollar price target and we have partnership already what going on
👍️0
sandtoes sandtoes 5 days ago
are molecule we be on top.
👍️0
Monroe1 Monroe1 6 days ago
Don't blink this fella is kicking ass >>> RFK Jr. Appoints Several Prominent Critics of COVID-19 Vaccines to Key Committee After Firing Entire Advisory Panel
by Jim H?ft Jun. 11, 2025 5:15 pm

https://www.thegatewaypundit.com/2025/06/rfk-jr-appoints-several-prominent-critics-covid-19/
👍️ 2
chumppunk chumppunk 6 days ago
Thanks Max L.
"Unlocking Immunotherapy for All”
"Checkpoint inhibitors changed oncology — but not for everyone. Leronlimab may unlock their power for the rest.”

In a recent post, I shared Cytodyn’s ESMO 2025 data in triple-negative breast cancer (TNBC): 88% of patients upregulated PD-L1 on circulating tumor cells (CTCs) and CAMLs after starting Leronlimab — a CCR5 inhibitor.

That’s striking and intriguing — especially considering that nearly 80% of TNBC patients are ineligible for immune checkpoint inhibitors (ICIs) due to PD-L1 negativity.

So how is a CCR5 inhibitor doing this?

As a physician-researcher, I’ve been deep-diving into Leronlimab’s dual mechanism of action — not only as an anti-metastatic agent, but also as a potential immunotherapy primer.

Here’s the working theory:

🔹 Tumor-intrinsic effects: Leronlimab blocks CCR5 on tumor cells, reducing migration, disrupting EMT, and enhancing CD4? T cell activity.
🔹 Immune reprogramming: It prevents CCR5-mediated recruitment of suppressive immune cells (Tregs, TAMs, MDSCs), promotes CD8? T cell activation, and increases IFN-? — which then drives PD-L1 upregulation as part of the normal immune cascade.
🔹 Peripheral biomarker potential: These immune shifts are mirrored in the blood — where PD-L1? CTCs and CAMLs may offer a non-invasive window into tumor reprogramming.

The result?
Some PD-L1–negative tumors may convert to PD-L1–positive, potentially making them eligible for checkpoint blockade — and giving more patients a shot at immunotherapy.
#TNBC #immunotherapy #leronlimab #PDL1 #CCR5 #oncology #TME #checkpointinhibitors #cancerimmunology #translationalresearch"
👍️ 6 😁 1
chumppunk chumppunk 6 days ago
looks like .35 the new MM #. EOM Chump
👍️ 2
Monroe1 Monroe1 6 days ago
Because they have existing drugs that have made billions because they work half assed or worse so as to add to the need for other medicine they also own to take care of the secondary effects. This is the scam of modern medicine for the past 75 years.

It's a real smart game they have down. Just enough "cure" to get approval... in some cases nada...then send out salesmen to schmooze the medical community.

In a perfect world... or one that we should be operating under, they would do what you mention. But cures and good medications don't offer near the long term profits. Fixing the problem cannot be shared by all these BP's, so the game is to help each club member to stay in business and milk the public.

RFK Jr. is a God send. Now listen to the backlash. They are the culprits those shouting the loudest. Many of those in Congress have reaped big bucks for many years and this cash cow is not going to be giving so much milk now. Leveling the playing field is going to help the world get healthier.

Once we have a partner of substance, watch the tide change rapidly. Some lucky partner will make billions for themselves and for CYDY.
👍️ 6 😃 1
Yki Yki 6 days ago
I dont know the real picture of manipulaation but wonder why those threathened would not buy a few million worth of stock and make billions if they knew this is such a threat.. or Just to minimise risks?
👍️ 2
Monroe1 Monroe1 6 days ago
Overall, as we all know, the leronlimab is a huge threat to many BP's not only for many existing sub par drugs but for those new ones in trials.They have billions of dollars just in hedge funds to attack any perceived threats. I look for more attacks. BlackRock and Vanguard have billions invested in these BP pigs.The firing of the CDC vaccine panelist the other day stimulated a hedge fund reactions shorting many lesser known pharmas the past two days. I have many that took a hit. Our time is approaching. When she rips she will tear the others a new butt hole. Gather all your troopers and pile on like a mad dog when the time comes so spread the word. Watch millions of shares get covered.
$$$CYDY$$$ 2025
👍️ 4
sandtoes sandtoes 6 days ago
time to let us fly.
👍️ 1
Monroe1 Monroe1 1 week ago
Educate yourself. Learning is living. Listen to this starting about 2:15 mark.
https://old.bitchute.com/video/cBpL8scGGYnE/

Out with the old guard and in with the new. $$$CYDY$$$ 2025
👍️ 4
Monroe1 Monroe1 1 week ago
Best move I have seen or read about in history within the US health system in my lifetime.

Those crooks have padded their asses on tax payer dollars for way too many decades.
We should have received a minimum of EUA for Covid. We should have received full
approval for HIV years ago. It's a real relief to see the pendulum swing in favor of facts
and truth. Now, put Fauci behind bars for mass murder as well for all the damage and losses
he has caused for many a non-club pharma company over the decades. We would have a pps
well above $50 were it not for him and his buds at the FDA/CDC/NIH/DARPA.

Going to be a lot of shorting of the pigs. I smell bacon frying.
$$$CYDY$$$ Fill my cookie jar with leronlimab.
👍️ 3
sandtoes sandtoes 1 week ago
this is a one hundred percent play.
👍️ 2
Monroe1 Monroe1 1 week ago
Breaking News
Breaking: RFK Jr. Removes All Members of CDC Vaccine Advisory Committee

HHS Secretary Robert F. Kennedy Jr. announced late today that he is retiring all 17 members of the CDC vaccine advisory committee. “A clean sweep is needed to re-establish public confidence in vaccine science,” Kennedy wrote in an op-ed published today in The Wall Street Journal.
by Brenda Baletti, Ph.D.Suzanne Burdick, Ph.D.
June 9, 2025

Yes sir. New days have come. Leronlimab will restore lots of confidence. Go CYDY. Hit it hard.
👍️ 4 🤣 1
Yahsho Yahsho 1 week ago
…..
👍️0
Monroe1 Monroe1 1 week ago
I am detecting some real nervousness with the shorts. It's Monday and no sell off?
Look at the average size of these trades... climbing. The MM's are doing a good job
for weeks now at buying for these clients while unloading their book of shorts at a nice profit.
Retail shorts and those working for some "analysts" are going to have a real awakening.
Could be a baptism by fire. Will be fun to watch. $$$CYDY$$$ Leronlimab the miracle molecule.
Statistically significant!!!
👍️ 1
Niknak1 Niknak1 1 week ago
Well Chump you and your Ghostbusters writing ✍️ is incredible. Long long read but I enjoyed every bit of it. I'm sure the G people were shaking in their boots. I love it. Keep up the good work. I don't even know why I said that because I know you will. Yes the ghost writer comes on like Buster's gang. But that's exactly what we need to Rattle the cages where the cages need rattled. I can actually see in my opinion at least these Bashers are slowly toning their selves down to a degree. Maybe someday we might even get an apology. But that's highly unlikely in my opinion now that I think about it. So long. Let's hope for some good volume this week.
👍️ 4 🤣 1
kgromax kgromax 1 week ago
Yep let's hide there while Cytodyn's SEC filings about the traditional quarterly dilution hits its victims (oops, sorry, public investors)
👍️0
Monroe1 Monroe1 1 week ago
Could be a good conference to attend.
https://www.keystonesymposia.org/conferences/conference-listing/meeting/program-highlights/F12026
Beautiful place too the town and the hotel.
👍️0
Monroe1 Monroe1 1 week ago
Ok pigeons come out of your coup. I want one more opportunity before I have to chase this baby.
Don't you just love this 6 month chart!!
I had a Sabado Gigante. Take it away Johnie Canales. You got it.
Johnie and our CEO Dr. J. $$$CYDY$$$ 2025 Shooting For The Stars
What's going on with Fidelity? Volume is over 3 times what they show.

https://www.cytodyn.com/pipeline
👍️ 4
sandtoes sandtoes 1 week ago
up,up we go no one can stop us.
👍️ 1
chumppunk chumppunk 1 week ago
Shorts on notice, it’s a happening.
Date and time for ESMO Barcelona CYDY abstract release
July 4th is the date of the CRC poster presentation (Observed Survival...) for the ESMO Gastrointestinal cancer conference. But the abstract will be published the night of June 25th, at 6:05 PM Eastern time. The ESMO site:

"All regular abstracts accepted for presentation at the ESMO Gastrointestinal Cancers Congress 2025 as Proffered Paper, Mini Oral, Poster, ePoster will be published online via the ESMO website at 00.05 CEST on Thursday, 26 June 2025."

In 18 days, the embargo over the content of the poster will be lifted. "Observed Survival." Sounds very good.
Chump
👍️ 8
chumppunk chumppunk 1 week ago
Another's points posted- "Vindication In The Making"
Welcome and Greetings to All of you.
A small addendum: In the title of yesterday's post, I put the word "Confirmation". Confirmation of what? Confirmation of what was already known. What was already known?
They had more than an inkling that leronlimab worked synergistically with check point inhibitors and they certainly pursued the MD Anderson pre-clinical trial to prove that out.
"26:12 SK: Yeah, so this is very exciting for us. So we signed an agreement with a major academic institution. We're not able to release it yet, because we got to prepare the press release and get their approval, but um but it's looking at leronlimab and checkpoint inhibitors and I think that's a very exciting thing because we're looking at synergistic opportunities with leronlimab. You know, just like HIV, Cancer is treated with multiple fronts, with multiple medications. We think this would be a checkpoint inhibitor would be perfect for this. We also think you could pair with a parp inhibitor and antibody drug conjugate, chemo, radiation. We don't think we'll see any drug interactions with leronlimab and those particular classes of drugs."
No, the MD Anderson findings were never disclosed. MD Anderson owned the data. CytoDyn was shown the data, but had to purchase it in order to reveal it and we all know there was no money back then for that. It was only murine data though, but it gave heading. Instead, we waited, but today, we have human data.
All the naysayers flooded the boards in criticism, but today, 5 remain alive. Why? Synergy. The Synergy that was appreciated in those mice which were administered an ICI following leronlimab treatment.
When Cyrus let us know on 3/14/2023 about this Synergy, he wasn't lying. The Synergy was real and palpable.
"Along with NASH, CytoDyn will focus primarily on oncology. Here, the company will target colorectal cancer and hormone receptor-positive, HER2-negative breast cancer.
These are both areas where checkpoint inhibitors have failed to show efficacy when added to a standard-of-care backbone, Arman said, adding that leronlimab has shown positive signals in both.
“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.
Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.
Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers."
Mazzy is day in and day out on her critical rant. Pretending expertise, she exhibits her lack of understanding. Everything is ass backwards when she open it. When she says fraud, think truth. When she says truth, think lie. What she labels as fabrication, know it as sheer fact, while her assembly of facts together are gobbledygook. Nothing she nor her cohorts say amounts to anything. And she has excuse after excuse.
She puts herself up on a pedestal, claims vast years of experience. Assigns herself all sorts of self worth. But, in the end, CytoDyn gets the last word.
Enter Dr. Lalezari:
"That fantastic day NP refers to has finally come.
"We are thrilled to announce this apparent mechanism behind the improved survival in patients with refractory and metastatic TNBC,” said Dr. Jacob Lalezari, CEO of CytoDyn. “Leronlimab’s ability to induce an inflamed or “hot” tumor environment, that could then be treated with ICIs, would be a game changer in solid tumor oncology. Prospectively confirming these findings in patients with TNBC is a top priority. We have also amended our current colorectal cancer trial to ensure the prospective collection of PD-L1 data in a second type of solid tumor."
Fact is, 5 of the original 28 are alive today. Full Stop. Should not have lived beyond 1 year, but they lived that, +4 more. Guess that is all fake, right Mazzy?
What, you don't like? The Confirmation of Hope? Time works its magic. Thank you NETpositive.
"...Our prayers are answered through vast spans of time where answers are met with a contentment that only passing time can grant.
Cydy’s journey is real, just like most life experiences. Its outcome will likely be different than what we have expected..."
The handwriting is on the wall and it spells out ICIs. Try to decipher or even read what we have already comprehended and understood. Until you can, it continues to fall apart for you Skeptic, Scoffer and Short. Every assumption you make, is shaken to its core by these tremors of truth.
OK, CytoDyn was put to trial and put through the fire, but in the end, the verdict still stands. Lion Lalezari roared loud and clear the Simple Synergy and Effectiveness of the new MOA.
Enough of this, let's move on.
Vindication in the Making? You mean, CytoDyn has not yet been vindicated? That's right. As NETpositive and Tatshensini River suggest,
"In essence, it's about having high hopes for oneself or something, aiming for a distinguished and impactful outcome."
Therefore, the achievement of that Vindication or "Eminence" takes time, therefore, it is in the Making.
If Vindication / Eminence were really to come to CytoDyn, then Cures of these horrible diseases would begin to take shape. A Cure of HIV, and a cure of mTNBC would begin to take shape and materialize as they now are. We may even be shooting for a Cure of MSS mCRC if what I'm thinking is to be discussed at GI ESMO in Barcelona on 7/4/25. Same Synergistic MOA in MSS mCRC as well? I think so.
If Cures do in fact start to materialize, then, competitors of CytoDyn begin to be diminished while CytoDyn begins its Upward escalation. The new US FDA, NIH administrations are now pro-Cure, which means Pro-CytoDyn, while Big Pharma remains anti-Cure and Pro-Treatment, Pro-Expensive Bandaids. The new administration is in negotiations with Big Pharma, but I don't think that goes very far. Unfortunately, or fortunately for CytoDyn, Big Pharma is deeply stuck in their ways.
CytoDyn is watching and waiting to see what comes of those negotiations and discussions. Their definitive actions and decisions might be paused to appreciate how exactly Big Pharma takes and implements their new administrative directives.
The biggest BP CytoDyn is concerned with is G. How shall G deal with the mandatory cut backs in their distribution of their main HIV medications worldwide? How does it deal with not being able to distribute their every 6 month PrEP medication to the HIV+ patients of the world?
We all know G is CytoDyn's arch rival. In every indication, G has stolen the show away from CytoDyn, not allowing not even the smallest of indications to get by, and they did it even with inferior drugs because they have padded the pockets of the prior administrators who signed their approvals. No doubt, they were behind Amarex and are still behind the shorts.
With that in mind, and if Vindication / Eminence were to come to CytoDyn, with Cures of HIV and of mTNBC already taking shape and soon to be made manifest, what would that do to G's money flow if HIV were Cured, if mTNBC were Cured? If Vindication / Eminence were to come in a PR, what would be said that would turn the tables around180 degrees from the imbalance which is in place today?
What would G's reaction to that PR be? More Mazzy attacks? No doubt, but she is voiceless anyway. More short attacks? Assuredly and they'll begin at first to double and triple down, even while the share price doubles and triples skyward. G has $$ to burn and burn it shall. But, they'll have more $$ to burn and they'll burn that all up as well, until they're all burnt up. To the point of being Blinded and Astonished by the Asteroid they never saw coming. They have lost sight of the shorting of which they're engaged in. Muscle memory is all they shall have to go on and that shall wipe them clean.
Since that is possible, that the PR is so hard hitting, that G finds themselves in dire need to retaliate, despite all the ammunition they throw at CytoDyn, it won't be enough to overcome the shareholder reaction to the implications of the PR. G wipes out their retaliatory efforts and are left muted and castrated.
Then, following that PR which comes, CytoDyn can move along. What PR comes?
The PR that incorporates this new Synergistic MOA into a partnership agreement with a prominent ICI manufacturer in a Phase 3 Clinical Trial against mTNBC. When that is announced, I think it comes to the point, that G realizes, they no longer can keep this thing suppressed, so they pull back and let it ride.
Now, given the fact that it was from even before Cyrus that CytoDyn knew something was happening with ICIs. Chris Recknor knew about the reduction of CTCs with leronlimab. Recently, Creatv Bio said this about CTCs and CAMLs in mTNBC, and they said this about the same biomarkers, but in MSS mCRC.
"CytoDyn has received FDA clearance to initiate a Phase II study of leronlimab in patients with relapsed or refractory micro-satellite stable colorectal cancer (CRC) (NCT06699835). The drug, leronlimab, targets CCR5 marker on the tumor.
*Creatv will perform the LifeTracDx***® *liquid biopsy in a number of CytoDyn studies including NCT06699835. The LifeTracDx***® test is based on analyzing two biomarkers: (1) circulating tumor cells (CTCs) and (2) Cancer Associated Macrophage-Like (CAML) cells, which are macrophages that engulf tumor cells. Both CTCs and CAMLs contain tumor material.
By tracking CTC and CAML counts, and CAML size at various time points, LifeTracDx® can provide prognostic insights and predict treatment response. CytoDyn is also interested in the expressions of CCR5 and PD-L1 markers on the tumor. *These markers can change over time. LifeTracDx***® *can provide this information by a blood test - no tissue is required. The LifeTracDx***® assay will help CytoDyn to better evaluate the effectiveness of their drug."
Chris Recknor was already aware of this. He worked with Creatv Bio when he was with CytoDyn. Take note their insignia lower right.
Are the two ESMOs virtually identical as far as a Synergistic MOA depending on an ICI together with leronlimab? Yes.
This synergistic MOA has been known for sometime, but is only being revealed today, because of PROOF of its efficacy. The proof is tangible, it is not theoretical. The people are alive today. They survived their cancers. They overcame their disease. These are Facts which can not be denied.
CytoDyn is setting their negotiation table. CytoDyn owns the cards. CytoDyn is negotiating. They could be doing it before ESMO Barcelona, or they do it following. Regardless, they are in a negotiating mindset / mode. Give and Take. Counter offers as well?
Cures are on the way and somehow, I don't see G as part of it, despite the potential which Trodelvy offers. This new partnership puts CytoDyn in the lead for a long time. Enemies back away because any attempt at an attack only results in further loss, so they give their blessings to the new entity.
The declaration of the new Synergistic MOA is a Sign that something else is coming. That something else is a PR that completely turns everything around 180 degrees amazingly all at once. Its hard for me to comprehend it really.
CytoDyn is setting the table of negotiation for that agreement to be signed. I mean look at how quiet CytoDyn is right now. I believe Scuffer is on point here and here.
"I think the lack of more aggressive promotional efforts is a choice by CYDY management, not an omission. And I do believe that management’s goals are in alignment with shareholders."
Can we not understand that when CytoDyn is at these conferences quietly, watching and waiting the US administration carry out their new directives for Big Pharma, CytoDyn, in the backdrop, plotting its course, negotiating its potential paths forward. Don't see this as coming to fruition way on down the road. We've already come so far and for so long. Now, It's time. The administration has caught on and is on board; Big Pharma won't have any part of it.
I'm just putting 2 and 2 together here. I'll let you figure it out on your own. I hope it was helpful. It does seem as though pieces are falling into place.
👍️ 5 💯 1 😀 1
Monroe1 Monroe1 1 week ago


collect money on the front, collect money on the back.
👍️0
docj docj 2 weeks ago
Green is good. Have a great weekend Chump.
👍️0
chumppunk chumppunk 2 weeks ago
Low volume today. EOM Chump
👍️0
sandtoes sandtoes 2 weeks ago
this will fly to heaven.
👍️ 1
kgromax kgromax 2 weeks ago
... at all times of the night...
Breaking news: Time zones exist outside your backyard.

Shocking, I know. Travel beyond your town sometimes. Or maybe never.
CYDY shareholders are the perfect mirror of the company. They are priceless LOL
👍️0
Since 2012 Since 2012 2 weeks ago
Exactly, living rent free in the minds of the bashers at all times of the night, priceless
👍️ 1 🤣 1
kgromax kgromax 2 weeks ago
This is the power of the pump.

Makes you believe in fairies and fairy tales.

Such naivety...
👍️0
djjazzyjeff djjazzyjeff 2 weeks ago
Zomg we are getting uplifting off the OTC thanks to the poster presentation??? Zomg so amazing I love cydy
👍️0
fung_derf fung_derf 2 weeks ago
And yet, shockingly the share price is going down on this great news!....it's almost as if someone was dumping their shares as they post about all the great things occurring.
👍️0
Since 2012 Since 2012 2 weeks ago
Reading skills, isn’t that what you been preaching lately, get some, and I am a long and I didn’t mention a partnership anywhere, anytime like you stated, glad to have fixed that for you
👍️ 1
kgromax kgromax 2 weeks ago
CAN someone remind me when the ESMO poster presentation is due? I am happily waiting for the promised simultaneous partnership announcement!

As I said to my wife : honey, his is a guaranteed multibagger - 5 patients survived longer than the square root of the age of the younger CYDY investor, without any control group and only in combo, it’s clear the stock will jump on the ESMO day!
👍️0
chumppunk chumppunk 2 weeks ago
docj- I believe so and I'm asking the same and more questions.
Chump
👍️0
sandtoes sandtoes 2 weeks ago
this will burst sky high.
👍️ 1 🤣 1

Your Recent History

Delayed Upgrade Clock